logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for GSK
FinSentS UK100
2 Mar 15 15:16:54
$GSK:LN Novartis Completes Series Of Transactions With GlaxoSmithKline #GLAXOSMITHKLINE PLC http://t.co/VO7GQTXYYz #LDN100
HotKeyTrading
2 Mar 15 15:00:03
Insiders Buying: $SBY $OME $ARG $GSK $FAST $CVO $COUP $AMRI $CLNE $HAS $MASI $ICE $UIHC $COG $ARC http://t.co/kl3VGOukhn #stocks #markets
The GMP Group
2 Mar 15 14:24:50
RT @fwpharma: View latest #pharma news covering $NVS, $GSK, $AMGN, Kyprolis, $JNJ, Takeda, Velcade, Gilead Sciences, Natco Pharma https://t…
FirstWord Pharma
2 Mar 15 14:20:19
View latest #pharma news covering $NVS, $GSK, $AMGN, Kyprolis, $JNJ, Takeda, Velcade, Gilead Sciences, Natco Pharma https://t.co/ZAMWWg1vGz
StocksBuzz
2 Mar 15 13:12:13
Look back at my tweets for $ohrp and $rent from last week .. $spy tlog $gsk $lgf #tv #media
biostock
2 Mar 15 13:07:55
Before March 18 FDA advisory meeting $GSK is gobbling shares. That shows their confidence in $THRX product $IBB $DIA $SPY
Jag Shur
2 Mar 15 12:43:20
GSK, Novartis complete billions of dollars in deals $GSK http://t.co/0I93508mzH
The GMP Group
2 Mar 15 12:25:13
RT @fwpharma: View today's #pharma news covering $NVS, $GSK, $AMGN, Kyprolis, $JNJ, Takeda, Velcade, Gilead Sciences, Natco Pharma https://…
HCSM News
2 Mar 15 12:21:01
View today's #pharma news covering $NVS, $GSK, $AMGN, Kyprolis, $JNJ, Takeda, Velcade, Gilead Sciences, Natco Pharma …
FirstWord Pharma
2 Mar 15 12:19:02
View today's #pharma news covering $NVS, $GSK, $AMGN, Kyprolis, $JNJ, Takeda, Velcade, Gilead Sciences, Natco Pharma https://t.co/ZAMWWg1vGz
Sleek Money
2 Mar 15 11:35:12
GlaxoSmithKline plc Receives Hold Rating from Baader Helvea $GSK http://t.co/bbiyZhtrw0
4-traders.com
2 Mar 15 10:44:04
#GlaxoSmithKline : Health and Human Services Department (HHS); Food and Drug A... http://t.co/O7aS9NyY56 $GSK
NASDAQ
2 Mar 15 09:43:04
$GSK - Report of Foreign Issuer (6-k) http://t.co/lnP50PZlOb
StockNews
2 Mar 15 09:43:03
$GSK - Report of Foreign Issuer (6-k) http://t.co/C9NuvcOl0I
The squibbster
2 Mar 15 09:27:53
Good news wrt $DVAX DSMB-2. Optimistic, but still weary that FDA and/or $GSK will kill it again regardless of data. Proceed w/ caution.
StockNews
2 Mar 15 09:16:09
$GSK - Report of Foreign Issuer (6-k) http://t.co/XtYvnnM2Rf
NASDAQ
2 Mar 15 09:16:07
$GSK - Report of Foreign Issuer (6-k) http://t.co/UcxLlrIxel
Art
2 Mar 15 09:07:29
@bradloncar @techwhitepapers Jefferies Yang had $AEGR a buy when over 100= FAIL.. $ISIS $ALNY $BIIB $GSK $RGLS $JNJ $AZN
Breaking News
2 Mar 15 08:52:03
$GSK: GlaxoSmithKline (GSK) Upgraded From Hold to Buy: http://t.co/xx89OFBvVb
The GMP Group
2 Mar 15 08:51:58
RT @fwpharma: From earlier: @GSK, @Novartis complete asset-swap transactions http://t.co/8Hz56KgrMx $GSK $NVS #pharma
FirstWord Pharma
2 Mar 15 08:51:16
From earlier: @GSK, @Novartis complete asset-swap transactions http://t.co/8Hz56KgrMx $GSK $NVS #pharma
Trader Daily
2 Mar 15 08:49:29
GlaxoSmithKline $GSK Upgraded From Hold to Buy http://t.co/NomfTgKENg
TheStreet Alerts
2 Mar 15 08:47:35
GlaxoSmithKline $GSK Upgraded From Hold to Buy http://t.co/3CZuS5InPS
FiercePharma
2 Mar 15 08:41:07
Post-Novartis deal, GSK's top dog in vaccines, consumer health. Now what? http://t.co/oxfnKcYjtZ $GSK $NVS #pharma by @CarlyHFierce
Lisa Welsh
2 Mar 15 08:36:07
RT @FiercePharma: GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge http://t.co/VIW95Eegyn $GSK $NVS #pharma by @TracyS…
PRISMAS Salud
2 Mar 15 08:35:33
RT @FiercePharma: GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge http://t.co/VIW95Eegyn $GSK $NVS #pharma by @TracyS…
Carly Helfand
2 Mar 15 08:32:24
Post-Novartis deal, GSK's top dog in vaccines, consumer health. Now what? http://t.co/5ihvjIzadm $GSK $NVS #pharma
FiercePharma
2 Mar 15 08:31:01
GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge http://t.co/VIW95Eegyn $GSK $NVS #pharma by @TracyStaton
John George
2 Mar 15 08:13:33
Sports teams are not the only ones making trades. $GSK, $NVS complete multibillion-dollar swap http://t.co/8vMilhPJdZ via @PHLBizJournal
John Smith
2 Mar 15 08:09:37
$ACUR surging 15% on upgrade -strong Egalet partner . #Euro #cncb #jimcramer $gsk $shpg $azn $c #investing #money #biotech $eglt $aria $kerx
David Miller
2 Mar 15 08:08:04
$NVS and $GSK complete their vaccines for oncology swap. Around the biotech world, fun begins modifying drug tracking spreadsheets.
Elizabeth Willis
2 Mar 15 07:50:12
GSK, Novartis complete billions of dollars in deals http://t.co/C0DQIKshQE $GSK $NVS
FinSentS UK100
2 Mar 15 07:16:36
$GSK:LN Novartis Completes Series Of Transactions With GlaxoSmithKline #GLAXOSMITHKLINE PLC http://t.co/TiOKUVZwR1 #LDN100
Media Sentiment
2 Mar 15 07:10:09
$GSK received a new alert. Find out why at http://t.co/nZwqReM0tj #stocks #daytrading #trading #mkt #NYSE #NASDAQ #markets 215
Market Int Center
2 Mar 15 07:08:54
GlaxoSmithKline PLC $GSK Showing Bullish Technicals With Support At $47.12 ( http://t.co/YFKc9PDeXA )
Stock Market Intel
2 Mar 15 06:41:59
Large Cap Stocks Traders Alert: $GSK $CLR $BBT $ESRX *Get Reports* http://t.co/n3eKuOGD0X
StockNews
2 Mar 15 06:40:12
$GSK - Report of Foreign Issuer (6-k) http://t.co/h4ES3A6gew
NASDAQ
2 Mar 15 06:40:06
$GSK - Report of Foreign Issuer (6-k) http://t.co/wQMInDAdhi
janet gale
2 Mar 15 06:39:04
$GSK - GlaxoSmithKline PLC Director/PDMR Shareholding http://t.co/yZIy4DjTnl
Shane Day
2 Mar 15 06:39:03
$GSK - GlaxoSmithKline PLC Director/PDMR Shareholding http://t.co/pedI7oAQf7
Large Void Bot
2 Mar 15 06:24:04
In Play: $LL, $NXPI, $FSL, $PCRX, $ATHX, $UWTI, $GDP, $OPK High Uncertainty: $SBGL, $RDS.B, $GSK
Business News Desk
2 Mar 15 05:56:21
$GSK and Novartis $NVS complete deals to reshape both drugmakers http://t.co/JZpbRihqje http://t.co/l70LzHmtpq
RNA_Biotech
2 Mar 15 05:45:29
$Isis Pharmaceuticals Earns $15 Million From $GSK for Advancing ISIS-TTR Rx http://t.co/CYgO0uZkUV
janet gale
2 Mar 15 05:35:53
$GSK - GlaxoSmithKline PLC Annual Report 2014 on Form 20-F http://t.co/yP0u5gqhui
ADVFN
2 Mar 15 05:35:53
$GSK - GlaxoSmithKline PLC Annual Report 2014 on Form 20-F http://t.co/NlYEU65kfQ
Shane Day
2 Mar 15 05:35:52
$GSK - GlaxoSmithKline PLC Annual Report 2014 on Form 20-F http://t.co/oMc9zxSSQB
invest correctly
2 Mar 15 05:30:57
GlaxoSmithKline plc CEO Andrew Witty’s Pay Cut By 46% $GSK http://t.co/SWzktTBI8A #GSK
WKRB News
2 Mar 15 05:27:42
GlaxoSmithKline plc Lifted to Buy at TheStreet $GSK http://t.co/olaIHZYX2C
Breaking News Now
2 Mar 15 05:21:04
$EXEL $GSK: Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) Zelboraf Combo ...: http://t.co/OJOIdb9K8D
BioInvest
2 Mar 15 05:10:55
$ISIS Receives $15 million milestone from $GSK for advancing ISIS-TTR to Phase II/III trials
				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.